Delandistrogene moxeparvovec-rokl (Elevidys) — Notification
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs Blue Cross NC coverage and coding notification for intravenous delandistrogene moxeparvovec-rokl (Elevidys) for treatment of Duchenne muscular dystrophy and applies to providers and billing departments submitting claims in North Carolina.
Added revenue codes 0891 and 0892 associated with HCPCS code(s).
Updated FDA approved use wording to clarify ambulatory patients ≥4 years and added/updated limitations of use per FDA labeling.
Added HCPCS code J1413 to dosing reference table effective 1/1/2024.
Coverage Criteria
Investigational / Not Covered
Not covered when ANY of the following applies:
Policy consistently states investigational stance across issuance history.
Elevidys (delandistrogene moxeparvovec-rokl) carries specific clinical precautions related to hepatic function and recent immune activation. Per FDA labeling, Elevidys is not recommended in patients with preexisting liver impairment defined as GGT > 2 x upper limit of normal or total bilirubin > upper limit of normal not due to Gilbert's syndrome, and it is also contraindicated in those with active hepatic viral infection because of the high risk of acute serious liver injury and acute liver failure. The label also advises against use within 4 weeks of vaccination and in patients with active or recent infection within 4 weeks due to immunogenicity and safety concerns.
BCBSNC considers the use of delandistrogene moxeparvovec-rokl (Elevidys) investigational for all indications. As a result, Elevidys is not covered by this policy because Blue Cross NC does not provide coverage for investigational services or procedures; medical necessity criteria do not apply.
Coding and Dosing
| J1413 | Delandistrogene moxeparvovec-rokl (Elevidys) intravenous infusion |
| 0891 | Revenue code: Special Processed Drugs - FDA Approved Cell Therapy |
| 0892 | Revenue code: Special Processed Drugs - FDA Approved Gene Therapy |
Provider Actions and Billing
Investigational — coverage denial risk
The use of delandistrogene moxeparvovec-rokl (Elevidys) is considered investigational for all indications, including treatment of Duchenne muscular dystrophy (DMD). As investigational, these services are not eligible for coverage and claims are at high risk for denial.
- Investigational — coverage denial risk: Services for delandistrogene moxeparvovec-rokl (Elevidys) are considered investigational and are not covered; submitters should expect claim denials.
- Billing/authorization note: Prior authorization is not applicable for investigational indications; however, providers should follow standard facility billing practices. HCPCS code for Elevidys: J1413.
- Documentation expectation: If submitting for review or for internal tracking, include FDA label reference, indication, dosing weight calculation, and any supporting clinical trial data; note that medical necessity criteria do not apply when a service is investigational.
Provider action — contact payer for case review
If you believe an exception or case review is warranted, contact Blue Cross NC Provider Services prior to administration and provide complete clinical documentation. Do not assume coverage — obtain written determination when possible before treatment.
- Provider action: Contact payer for case review or exception requests prior to treatment.
- Operational note: Medical necessity criteria are listed as not applicable for investigational use; supplying comprehensive documentation does not guarantee coverage.
Documentation expectations and coding guidance
When submitting supporting materials (for internal request or exception review), include the FDA package insert details: indicated population, dosing regimen (10 to 70 kg: 1.33 x 10^14 vg/kg or 10 mL/kg; ≥70 kg: 9.31 x 10^15 vg/kg), HCPCS J1413, and any relevant revenue codes (0891, 0892) used by the facility.
- Documentation to supply: FDA label reference, dosing calculation and patient weight, indication (ambulatory vs non-ambulatory DMD status), and clinical evidence supporting use.
- Billing/coding guidance: Use HCPCS code J1413. Other applicable revenue codes: 0891, 0892.
Background
Delandistrogene moxeparvovec-rokl (Elevidys) is an intravenous gene therapy indicated by the FDA for treatment of ambulatory patients with Duchenne muscular dystrophy (DMD) aged ≥ 4 years. The product is administered as a single IV infusion; FDA dosing references are 10–70 kg: 1.33 x 10^14 vector genomes (vg)/kg (10 mL/kg) and ≥ 70 kg: 9.31 x 10^15 vg total. The policy references HCPCS code J1413 for billing and notes applicable revenue codes 0891 and 0892.
Definitions
Initial Therapy Criteria
Dosing / Initial therapy (label reference)
HCPCS J1413 referenced for billing.
Site of Care
Site-of-care requirement — hospital outpatient administration
Infusion must be administered by a healthcare professional in an appropriate clinical setting; the policy lists the site of care as hospital outpatient for this restricted product.
- Arrange administration in a hospital outpatient setting with qualified clinical staff.
- Follow institutional protocols for IV gene therapy administration and monitoring.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.